期刊文献+

利培酮对精神分裂症患者执行功能的影响 被引量:3

Effection of executive function in schizophrenic patients treated with Risperidone
下载PDF
导出
摘要 目的探讨利培酮对精神分裂症患者执行功能的影响。方法对83例精神分裂症患者进行利培酮(3~6mg.d-1)治疗8周,治疗前后进行威斯康星卡片分类测验(WCST)、阳性与阴性症状量表(PANSS)测验,并与65例正常人对照。结果治疗前治疗组与正常对照组在反映前额叶执行功能WCST指标的比较,治疗组WCST中各项指标测验成绩均较对照组差(P〈0.05或P〈0.01)。利培酮治疗前后治疗组WCST测验成绩除了分类数、正确数和非持续错误数无统计学意义外,错误数、持续错误数测验分数均较治疗前明显下降(P〈0.01);阳性与阴性症状量表分数均明显降低(P〈0.01)。结论精神分裂症患者存在执行功能障碍,利培酮对精神分裂症患者的执行功能有改善作用。 OBJECTIVE To explore the effects of Risperidone on executive function in schizophrenic patients.METHODS Compare the scores of Wisconsin Card Sorting Test(WCST)and Positive and Negative Syndrome Scale(PANSS)between 83 schizophrenic patients treated with Risperidone(3~6mg·d-1)for 8 weeks and 65 normal persons as controls.RESULTS Before treatment the WCST scores of patients are lower than controls significantly(P0.05,P0.01).In comparerison the patients and the controls,there are significant differences between before treatment and after treatment with Risperidone in patients except Categories Complets,Right Scores and Random Errors,Total Errors,Preservative Errors are lower than before treatment.Scores of PANSS are siginificant lower after treatment.CONCLUSION There are executive function disorder in schizophrenic patients.The Risperidone is useful for treatment of schizophrenia′s excutive function.
出处 《海峡药学》 2011年第9期79-80,共2页 Strait Pharmaceutical Journal
基金 宁波市医学科技计划项目(No.2004050)
关键词 利培酮 精神分裂症 执行功能 Risperidone Schizophrenia Executive function
  • 相关文献

参考文献7

二级参考文献46

  • 1胡一文,王高华,王惠玲,舒畅.首发精神分裂症患者认知功能与阴性症状的相关性[J].中国临床康复,2005,9(12):52-53. 被引量:16
  • 2郭起浩,张明园.精神分裂症的认知功能损害[J].临床精神医学杂志,1996,6(1):45-47. 被引量:25
  • 3[3]Harvey P.Optimising cognitive function in patients with schizophrenia.Gardiner-caldwell communication Ltd,1997
  • 4[4]Heaton P K.Wisconsin card sorting test manual.Psychologial assessment resources,Inc.Odessa,1981,39~52
  • 5[5]Stip E.The effect of risperidone on cognition in patients with schizophrenia.Can J Psychiatry,1996,41(2):35~40
  • 6[6]Gallhofes B,Kreager S,Lis S,et al.Cognitive dysfunction in schzophrenia:prefrontal-subcortical interaction as paradigm to assess the deficit and its possible remedy.Br J Psychiatry,1995,166:231~233
  • 7[7]Green M F.Schizophrenia from a neurocognitive perspective:probing the impentrable darkness.Allyn SL bacon viacom company,1988,22~28
  • 8舒良,中华神经精神科杂志,1987年,20卷,43页
  • 9Hugdahl K, Rund B R, Lund A, et al. Attentional and Executive Dysfunctions in Schizophrenia and Depression: Evidence from Dichotic Listening Performance. Society of Biological Psychiatry, 2003, 53: 609-616
  • 10Nathaniel-James D A, Brown R, Ron M A. Memory impairment in schizophrenia: its' relationship to executive function. Schizophrenia Research, 1996, 21: 85-96

共引文献380

同被引文献37

  • 1杜兆洪.维思通和氯氮平对血清甲状腺素水平检测的比较[J].实用医技杂志,2004,11(8):1020-1021. 被引量:3
  • 2舒畅,王高华,王惠玲,李洁,王得志.精神分裂症症状与威斯康星卡片分类测验成绩的相关性[J].中国心理卫生杂志,2004,18(8):580-582. 被引量:8
  • 3Furtner J, Prayer D, Sachs G. Functional MRI in schizophrenia. Diagnostics and therapy monitoring of cognitive deficits of schizophrenic patients by unctionai MRI[J].Radiologe, 2010, 50(2) : 131- 135.
  • 4Woodward ND, Purdon SE, Mehzer HY, et al. A meta-analysis of neuropsychological change to coza- pine, olanzapine, quetiapine, and Risperidone in schizophrenia [J].Int J Nenropsychopharmacol, 2005, 8(3) :457-472.
  • 5姚芳传,王克威.精神科查房手册(第一版)[M].南京:江苏科学技术出版社,2003:348-350.
  • 6Barch DM. Pharmacological strategies for enhancing cognition in schizophrenia[J].Curr Top Behav Neurosci, 2010, 4(4): 43-96.
  • 7Gurpegui M, Avarez E, Bousono M, et al. Effect of olanzapine or risperidone treatment on some cog- nitive functions in a one-year follow-up of schizo- phrenia outpatients with prominent negative symp- toms [J].Eur Neuropsychopharmaeol, 2007, 17 (11) :725-734.
  • 8Bender S, Dittmann-balcar A, Schall U, et al. In- fluence of atypical neuroleptic on executive functio- ning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs clozapine [J]. Int J Neurop sychopharmacol, 2006, 9 (2): 135-145.
  • 9Purdon SE, Jones BD, Stip E, et al. Neuropsycho- logical change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol[J]. Arch Gen Psychiatry, 2000, 57.
  • 10Stip E, Chouinard S, Boulay LJ. On the trail of a cognitive enhancer for the treatment of schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(2) :219-232.

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部